Legal & General Group Plc Takes Position in Amylyx Pharmaceuticals, Inc. $AMLX

Legal & General Group Plc purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 56,477 shares of the company's stock, valued at approximately $1,014,000. Legal & General Group Plc owned 0.05% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Landscape Capital Management L.L.C. lifted its position in Amylyx Pharmaceuticals by 17.5% during the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company's stock valued at $148,000 after purchasing an additional 1,825 shares during the period. KBC Group NV purchased a new stake in Amylyx Pharmaceuticals in the first quarter valued at $26,000. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the 4th quarter worth about $25,000. State of Wyoming acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth about $40,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Amylyx Pharmaceuticals by 13.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company's stock valued at $326,000 after buying an additional 3,198 shares during the last quarter. 95.84% of the stock is owned by institutional investors.

Insider Activity at Amylyx Pharmaceuticals

In related news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares of the company's stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.90% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AMLX. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday, August 18th. Guggenheim raised their target price on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a "buy" rating in a report on Thursday, August 27th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Wolfe Research raised Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Finally, Robert W. Baird upped their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $36.50.

Amylyx Pharmaceuticals Stock Performance

AMLX stock opened at $34.10 on Tuesday. Amylyx Pharmaceuticals, Inc. has a 12-month low of $9.75 and a 12-month high of $41.14. The business's 50-day moving average is $24.54 and its 200 day moving average is $18.35. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of -23.85 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). As a group, equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.